Company ProfilePremium

Nib Holdings Limited

Company Profile Analysis

Ticker: NHF.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Nib Holdings Limited - Company showcase

Year Founded & Workforce

1952

Nib Holdings Limited logo

Nib Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Nib Holdings Limited Overview

nib is Australia's fourth/fifth-largest private health insurer by market share and a leading trans-Tasman health funder, covering 1.95 million people across Australia and New Zealand at 30 June 2026. Its core is the Australian Residents Health Insurance (arhi) business — a digitally led, multi-channel insurer that has consistently grown above system through brokers, comparison sites, white-label partners and its own brand. Around this core nib has built "adjacent" businesses: International health insurance for students and temporary workers (including the Pacific Australia Labour Mobility scheme), nib New Zealand, NDIS plan management (nib Thrive) and nib Health Services (Honeysuckle Health, Midnight Health, ItsMyGroup). In FY26 it completed its exit from travel insurance, sharpening its identity as a pure-play health insurance and health services group. Its strategic thesis — moving from "payer to partner" — is to use data, AI, provider networks and health management programs to lower costs and improve outcomes, defending margins in a regulated, inflationary industry.


Company's own description

In its interim report, nib describes the Group's principal activities as being a private health insurer in Australia and New Zealand, underwriting and distributing private health insurance to residents and to international students, workers and visitors, alongside complementary health and disability-related services (2026 Interim Report, Directors' Report). The FY26 results announcement frames the mission as helping customers "access and navigate healthcare with confidence", with a stated forward focus on customer value, affordability, access to care, sustainable growth, provider partnerships, care navigation, and the use of technology, data and AI (FY26 ASX Announcement, CEO statement).

Independent characterisation

nib is fundamentally a short-tail, community-rated health insurance underwriter whose earnings are driven by (i) policyholder growth, (ii) the annual government-approved premium increase (5.47% effective 1 April 2026), (iii) claims inflation and utilisation, (iv) risk equalisation transfers in the Australian community-rated system, (v) operating expense efficiency, and (vi) investment returns on regulatory capital and float. Around 78% of FY26 insurance revenue came from the Australian residents business ($3,012.7m of $3,685.7m Group insurance revenue — FY26 ASX Announcement).

Revenue model mix (FY26)

Revenue typeFY26 (AUD Mn)Share of total income (%)Nature
Insurance revenue (all insurance segments)3,685.795.6Premium-based, annual/monthly policies (subscription-like recurring revenue)
Other income169.14.4Fees (NDIS plan management fees at nib Thrive $55.0m), health services operating income ($25.4m), distribution commissions, other
Total income3,854.8100.0—

Source: FY26 ASX Announcement, Group financial performance table. Net investment income ($57.0m) is reported below operating profit and is excluded from "total income" above.

Value-chain position

nib sits at the funder/payer layer of the health value chain: it collects premiums, pays benefits to hospitals, medical specialists and extras providers (dental, optical, physio, audiology, mental health), and increasingly contracts with providers (multi-year hospital agreements covering >80% of hospital spend per 1H26 webcast; "First Choice" preferred-provider network; Known Gap/No Gap specialist arrangements). Through Health Services it moves into care navigation and delivery (telehealth, virtual health management programs via Honeysuckle Health, Midnight Health) and distribution technology (ItsMyGroup platform supporting 18 PHI brands and facilitating >10% of industry PHI sales — FY26 ASX Announcement).

Customer types and end-markets

Customer typeSegmentEnd-market
Australian resident individuals, couples, familiesarhiAustralian private health insurance (hospital + extras)
International students (OSHC), temporary graduates, skilled workers, PALM scheme workersInternational health insuranceAustralian overseas visitor/student health cover; NZ international cover
New Zealand residents (individual and corporate/group schemes)nib New ZealandNZ private medical, life and living insurance
NDIS participants (plan management)nib ThriveAustralian disability services (NDIS plan management)
Insurers, employers, governments (B2B), and nib membersnib Health ServicesHealth management programs, telehealth, PHI distribution technology
White-label partners, brokers, comparison sitesDistribution across segmentsIntermediated insurance distribution
Travellers (until Sept 2026)nib Travel (divested)Travel insurance — now distribution-only via Allianz Partners partnership

Strategy

Stated strategic themes (FY25–FY26 reporting)

  1. Customer-first, digital-led: Over 70% of Australian PHI policies connected digitally (FY25); 86.3% claims automation (FY26).

  2. Payer to partner: Shifting from passive funder to active partner in health outcomes — provider partnerships, care navigation, health management programs.

  3. Focus on core: Exit from travel to concentrate capital on health insurance and health-adjacent businesses in ANZ.

  4. Productivity & performance agenda: $18m savings (FY25); cumulative $39m by 1H26; $61m of value created in FY26.

  5. AI and data: 50+ AI/ML initiatives (FY25); nibGPT used by 700+ operational staff; automated call summaries (FY26).

  6. Sustainable, high-quality growth: Prioritising Silver-tier, long-tenure customers; reviewing partner/white-label economics alongside brand and direct investment.

Initiatives register (last 24 months)

InitiativeDateDescriptionStatus
CEO transitionDec 2024Ed Close succeeds Mark FitzgibbonComplete
nib Travel strategic reviewMay 2025 – Sep 2026Review and sale of all travel businessesComplete
NZ recovery planFY25–FY26Repricing, product changes, benefits managementUOP restored to $27.5m
Productivity, digital & AI agendaFY24 onwardsSimplification, automation, AI deployment$61m value FY26
Long-term hospital agreementsFY25–FY26Multi-year contracts covering >80% of hospital spendOngoing
First Choice network expansionFY26Added audiology and mental health providersOngoing
Health management programsFY25–FY2622,300+ customers participated (FY26); 93% delivered virtually (1H26)Scaling
Allianz Partners distribution partnershipJun 2026Long-term distribution of nib-branded travel insurance (commission-based)Commenced Sept 2026
Capital managementAug 2026Payout ratio raised to 65–75%; 5c special dividend; further optionality from Travel proceedsActive

Medium-term targets / guidance (FY27)

  • Group UOP $265m–$285m excl. nib Travel, subject to risk equalisation (vs FY26 UOP excl. Travel of $256.1m).

  • Significantly lower one-off costs; further improvement in Group operating expense ratio.

  • arhi: sustainable high-quality policyholder growth; underlying net margin 6–7%; broadly stable gross margin.

  • International and NZ: ongoing strong contributions; Health & Insurance Services: positive UOP growth.

  • Dividend payout ratio target 65–75% of NPAT.

Source: FY26 ASX Announcement, FY27 Outlook.

Products & Services

Australian Residents Health Insurance

Product / brandDescriptionTarget customerPricing modelNotes
nib Hospital covers — GoldComprehensive hospital cover across all clinical categories required under the PHI tier systemFamilies, older customers, those planning major treatmentCommunity-rated annual premium, varies by state/excessTiering per 2019 federal reforms
nib Hospital covers — Silver (incl. Silver Plus)Mid-tier hospital covers; strategic target categoryYoung families, value-seeking customersPremium + excess85% of FY26 net growth came through Silver vs 46% in FY25 (FY26 webcast)
nib Hospital covers — Bronze / BasicEntry-level hospital covers, often purchased to avoid Medicare Levy SurchargeYounger singles, tax-motivated buyersLower premiums, higher excessDeliberately de-emphasised in FY26 portfolio mix
nib Extras coversDental, optical, physiotherapy, chiropractic, audiology, mental health and other ancillary benefitsBroadAnnual limits per categoryFirst Choice network delivers no/low gap
Combined packagesBundled hospital + extrasFamiliesBundled premium—
First Choice provider networkPreferred dental, optical, audiology and mental health provider networkAll extras holdersNegotiated provider feesSaved customers $57m in out-of-pocket costs in FY26
Known Gap / No Gap specialist arrangementsPre-agreed specialist gap feesHospital membersContractedHighlighted in FY25 presentation
White-label PHInib-underwritten products sold under partner brandsPartner customer basesPartner distribution feesPartner economics under review in FY26
Digital channels (nib app, online claims)Digital servicing; 86.3% of claims automated, 94.8% processed within 24 hours (FY26)All—NPS +32

International Health Insurance

ProductDescriptionTarget customerNotes
Overseas Student Health Cover (OSHC)Visa-compliant cover for international studentsStudent visa holdersDemand linked to student visa caps/policy
Overseas Visitors / Workers Health CoverCover meeting visa condition 8501 for temporary workersSkilled workers, temporary graduatesGrowth driver in FY26
PALM scheme coverHealth cover for Pacific Australia Labour Mobility workersPacific/Timor-Leste seasonal and long-term workersPolicyholder growth driver in FY26
NZ international coverCover for international workers/students in NZNZ visa holders—

FY26: insurance revenue $236.9m (+7.4%), UOP $35.1m (+15.1%), policyholder growth 4.4%, NPS +62 (FY26 ASX Announcement).

nib New Zealand

ProductDescriptionNotes
Individual health insuranceSurgical, hospital and everyday coversRepriced in FY25–FY26 to restore profitability
Corporate/group health schemesEmployer-sponsored health plans—
Life & living insuranceLife cover, trauma, income protection—
Benefits managementUtilisation management initiativesUtilisation inflation cut to 4% from 10% in 1H26

FY26: insurance revenue $429.4m (+7.0%), UOP $27.5m (FY25: −$2.9m), claims inflation moderating to 12%, NPS +2 (1H26) to +25 (2H26).

nib Thrive

ServiceDescriptionNotes
NDIS plan managementFinancial administration of NDIS plans: invoice processing, provider payment, budget tracking40,000+ participants supported in FY26; 42,070 at 31 Dec 2025 (down 6.9%), with positive growth returning in Jan 2026
Participant support / digital toolsPortal/app for budget trackingInvestment in service capability and technology during sector reform

FY25: processed 3.4m claims worth $2.5bn (FY25 announcement). FY26: fee income $55.0m, UOP $16.3m.

nib Health Services

BrandDescriptionKey metricsOwnership notes
Honeysuckle HealthHealth data analytics and virtual health management programs (chronic disease, pre/post-operative, weight/metabolic) sold to nib and external clients18,500+ program enrolments (FY26); external client satisfaction +91.3Originally JV with Cigna; current ownership structure to be verified in 2026 Annual Report
Midnight HealthTelehealth / digital health platform (direct-to-consumer treatments)Part of >150,000 telehealth consultations facilitated across the Group in FY26Partnership/ownership interest led by Ed Close pre-2024
ItsMyGroupPHI distribution and technology platform (comparison/advice, AI-enabled sales capabilities)Supports 18 PHI brands; facilitates >10% of industry PHI sales—

FY25: Honeysuckle Health and Midnight Health combined gross revenue $70.2m (+51.6%) (FY25 announcement). FY26: segment operating income $25.4m (+46.0%), UOP $2.4m.

nib Travel (divested)

BrandDescriptionDisposition
World NomadsGlobal adventure travel insurance brandSold to International Medical Group (SiriusPoint) for $67.5m; completed 30 Sep 2026
Travel Insurance Direct (TID)Direct online travel insurance (AU/NZ)Sold to Allianz Partners; completed 17 Sep 2026
nib Travel (incl. partnerships, white label)nib-branded and partner travel insuranceUnderwriting/partnerships sold to Allianz Partners; nib continues to distribute nib-branded travel insurance under a long-term (20-year white-label, per ITIJ) partnership

Financial Narrative

Income statement

Sources: 2025 Notice of AGM five-year table (revenue FY22–FY25, DPS, payout ratios); FY22 ASX Announcement (UOP $235.3m, NPAT $133.8m); FY23 ASX Announcement (UOP $263.2m, NPAT $191.8m per Insurance Business reporting of announcement, revenue $3.1bn); FY25 ASX Announcement (UOP FY24 $257.5m, FY25 $239.2m, NPAT FY24 $181.6m, FY25 $198.6m, EPS 41.1c); FY26 ASX Announcement (all FY26 and restated FY25 P&L lines). FY26 revenue shown is "total income" ($3,854.8m) per the FY26 financial table; company headline "Group revenue $3.8 billion, +6.2%".

Data conflicts flagged:

  • FY26 basic EPS of 38.3c is derived (NPAT $186.9m ÷ ~487.7m shares) — verify against Appendix 4E.

  • FY22–FY23 are AASB 1023 basis; the 2025 Notice of AGM five-year table (AASB 17 restated where applicable) contains NPAT values (e.g., 108.5 and 205.7) that do not reconcile to originally reported FY22/FY23 NPAT; the originally reported figures are used above. Payout ratios (74.4% FY22, 68.7% FY23) imply EPS consistent with the originally reported NPAT.

  • FY23 UOP of $263.2m was reported under AASB 1023; the AASB 17-restated FY23 comparative used in FY24 reporting may differ.

Margins and growth

Calculated from 6.1. Revenue CAGR FY22–FY26: ~8.4% p.a. (2,788.6 → 3,854.8; note FY26 definition is total income). Company-reported growth rates differ slightly (FY23 +10.9%, FY25 +7.8%, FY26 +6.2%) due to definitional changes and restatements.

Gross profit / EBITDA: Not reported by nib. As an insurer, nib reports insurance service result, UOP and statutory operating profit rather than gross profit or EBITDA; these are marked not publicly disclosed.

Balance sheet

Sources: InvestSMART financial summary (equity FY23–FY25); FY26 ASX Announcement (debt, gearing, leverage); FY26 Investor Presentation (PCA ratio 1.65x).

Commentary: Debt fell by $71.8m in FY26 to $204.8m, gearing improved 490bps to 15.2%, and leverage reached 0.6x — the strongest balance-sheet position in recent years. The prudential capital ratio (PCA coverage 1.65x for nib health funds) sits comfortably above typical internal targets. Travel sale proceeds (~$97m net, received in 1H27) will further de-gear or fund capital management.

Cash flow: notes and sources

Sources: FY26 ASX Announcement (net operating cash); InvestSMART (premiums received). Dividends paid in cash: 1H26 interim dividend $63.4m (2026 Interim Report); 2H26 special component ~$24m (FY26 ASX Announcement).

Ratios

Sources: InvestSMART (ROE FY23–FY25); FY26 ASX Announcement. Current ratio, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful/not reported for a health insurer; interest coverage can be approximated as statutory operating profit ÷ net finance costs = ~15.1x in FY26 (215.7/14.3) — derived.

Trend commentary

Revenue: Steady 6–10% annual growth driven by policyholder growth and annual premium increases (5.47% from 1 April 2026). Revenue growth has decelerated modestly as nib deliberately traded volume for mix (Silver focus) and as arhi net policyholder growth slowed from 3.2% (FY25) to 1.9% (FY26).

UOP inflection: UOP peaked at $263.2m (FY23, AASB 1023) amid COVID-era claims deferral, dipped to $239.2m in FY25 as arhi margins were guided down toward 6–7% and NZ fell into loss, then recovered to $260.9m in FY26 on NZ turnaround (+$30.4m), International growth and productivity savings ($61m of value created in FY26).

Mix shift: arhi UOP declined two years running (217.8 → 207.8 → 187.9) while adjacent businesses rose from $45.3m (FY25) to $86.1m (FY26) — a material diversification of earnings.

NPAT vs UOP divergence: FY26 NPAT fell 5.9% despite UOP +9.1% because net investment income dropped $22.0m to $57.0m, one-off/M&A costs were $23.7m, amortisation of acquired intangibles rose to $16.7m and the effective tax rate rose.

Expense discipline: Operating expense ratio fell 110bps to 16.6%; arhi non-marketing expense ratio of 5.3% is the lowest since 2007.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsKey products / services

Australian Residents Health Insurance (arhi)

nib-branded and white-label private health insurance for Australian residents

Hospital (Gold/Silver/Bronze/Basic tiers), extras, combined covers; First Choice network; Known Gap/No Gap specialist arrangements

International Health Insurance (formerly iihi)

Cover for international students, temporary graduates, skilled workers, PALM scheme workers in Australia and NZ

Overseas Student Health Cover (OSHC), Overseas Visitor Health Cover (OVHC), worker cover

nib New Zealand

Private medical insurance plus life and living (risk) insurance for NZ residents and groups

Individual and corporate health plans; life, income, trauma covers

nib Thrive

NDIS plan management

Plan management, claims processing, participant support

nib Health Services

Health management, telehealth and PHI services platform

Honeysuckle Health, Midnight Health, ItsMyGroup

nib Travel (discontinued, sold Sept 2026)

Travel insurance

nib Travel, Travel Insurance Direct (TID), World Nomads

Segment revenue (AUD Mn)

Segment revenue (AUD Mn)FY25FY26

arhi insurance revenue

2,832.63,012.7

International health insurance revenue

220.6236.9

nib New Zealand insurance revenue

401.4429.4

nib Thrive fee income

57.155.0

nib Health Services operating income

17.425.4

Revenue by Segment

Segment UOP (AUD Mn)FY24FY25FY26

arhi

217.8207.8187.9

International health insurance

24.830.535.1

nib New Zealand

—-2.927.5

nib Thrive

—16.916.3

nib Health Services

—-5.92.4

nib Travel (discontinued)

8.16.74.8

Group UOP (incl. Travel)

257.5239.2260.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment (FY26) Overview

Segment (FY26)UOP margin on revenue (%)Revenue YoY (%)UOP YoY (%)Share of Group UOP (%)

arhi

6.26.4-9.672.0

International

14.87.415.113.5

nib NZ

6.47.0

n.m. (loss to profit)

10.5

nib Thrive

29.6 (on fee income)

-3.7-3.66.2

nib Health Services

9.4 (on operating income)

46.0

n.m. (loss to profit)

0.9

nib Travel

——-28.41.8

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Group underlying revenue (AUD Mn)

2,788.63,051.03,337.23,599.23,854.8

Insurance revenue (AUD Mn)

———3,461.43,685.7

Incurred claims (AUD Mn)

———2,740.22,947.3

Total operating expenses (AUD Mn)

———638.2633.7

Underlying operating profit UOP (AUD Mn)

235.3263.2257.5239.2260.9

Statutory operating profit (AUD Mn)

———198.7215.7

Net investment income (AUD Mn)

———79.057.0

Net finance costs (AUD Mn)

———18.514.3

Profit before tax (AUD Mn)

———259.2258.4

Net profit after tax (AUD Mn)

133.8191.8181.6198.6186.9

Basic EPS (A cents)

———41.138.3

Dividend per share incl. special (A cents)

22.028.029.029.034.0

Ordinary dividend per share (A cents)

22.028.029.029.029.0

Dividend payout ratio ordinary (%)

74.468.775.770.6—

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

UOP margin on revenue (%)

8.48.67.76.66.8

NPAT margin on revenue (%)

4.86.35.45.54.8

Revenue growth YoY (%)

7.29.49.47.97.1

Operating expense ratio (%)

———17.716.6

arhi hospital benefits payout ratio (%)

————88.8

Claims inflation arhi (%)

————4.1

Balance Sheet and Margin Analysis (%)

MetricFY2023FY2024FY2025FY2026

Shareholders' equity (AUD Mn)

980.91,042.81,111.1—

Interest-bearing debt (AUD Mn)

——276.6204.8

Gearing ratio (%)

——20.115.2

Leverage ratio (x)

——0.80.6

nib health funds PCA coverage (x)

———1.65

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Net operating cash flow (AUD Mn)

———165.7199.1

Premiums received (AUD Mn)

—3,2173,5263,733—

Dividends declared per share (A cents)

22.028.029.029.034.0

Margin Analysis (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025FY2026

Return on equity (%)

21.120.818.1—

Gearing (%)

——20.115.2

Leverage (x)

——0.80.6

Operating expense ratio (%)

——17.716.6

Non-marketing expense ratio arhi (%)

———5.3

Region revenue (AUD Mn)

Region revenue (AUD Mn)FY2024FY2025FY2026

Australia — residents (arhi)

—2,832.63,012.7

Australia/NZ — International health insurance

—220.6236.9

New Zealand — nib NZ

371.3401.4429.4

Region growth (%)

Region growth (%)FY2025FY2026

Australia — arhi revenue growth

7.36.4

International health insurance revenue growth

14.47.4

New Zealand revenue growth

8.17.0

Share Price

MetricFY2021FY2022FY2023FY2024FY2025FY2026

Share price October (AUD)

6.626.677.245.787.546.45

Valuation Snapshot

MultipleValueBasis

Market cap (AUD Bn)

~3.15

487.7m shares

P/E (trailing)

~16.8x

FY26 EPS 38.3c (derived)

Dividend yield (trailing, incl. special)

~5.3%

34.0c

Dividend yield (ordinary)

~4.5%

29.0c, fully franked

P/B

~2.6–2.8x

—

EV/EBITDA, EV/Sales

Not meaningful for insurer / not computed

—

Analyst consensus target

A$7.71

Simply Wall St (Aug 2026)

Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Interim dividend (A cents)

11.0——13.013.0

Final dividend (A cents)

11.0——16.021.0

Total dividend (A cents)

22.028.029.029.034.0

Analyst Conclusions

Management guidance (FY27)

Group UOP $265–285m excl. nib Travel (subject to risk equalisation); lower one-offs; improved OER; arhi net margin 6–7% with broadly stable gross margin; strong International/NZ contributions; positive UOP growth in Health & Insurance Services.

Bull case

  1. Earnings diversification is real: Adjacent UOP nearly doubled to $86.1m; NZ swung +$30.4m and International grew 15.1% — reducing dependence on arhi margins.

  2. Productivity flywheel: $61m value in FY26, OER down 110bps, and further OER improvement targeted; lower one-offs in FY27 should lift statutory earnings closer to UOP.

  3. Capital returns: Higher payout ratio (65–75%), ~5.3% trailing yield and ~$73m of undeployed sale proceeds support shareholder returns, with gearing at only 15.2%.

Bear case

  1. Core arhi erosion: arhi UOP has fallen two consecutive years (−9.6% in FY26) and policyholder growth undershot the ~3% target at 1.9%.

  2. Earnings quality/volatility: Risk equalisation, rebate/levy adjustments and investment income (−27.8%) make NPAT unpredictable; NPAT declined in FY26 despite UOP growth.

  3. Regulatory and cost pressure: Hospital payout ratio 88.8%, political scrutiny of premiums and NDIS reform risk could cap margins.

Catalysts & monitorables (next 12 months)

  • 2026 AGM (Oct/Nov 2026) — trading commentary, El-Ansary election.

  • Deployment of remaining Travel proceeds (special dividend, buyback or bolt-on).

  • 2027 premium round outcome (announced ~Feb 2027, effective 1 Apr 2027).

  • 1H27 results (~Feb 2027): arhi policyholder growth vs target, risk equalisation, NZ margin durability.

  • NDIS plan management reform implementation and Thrive participant trends.

  • Industry claims inflation trajectory vs nib's 4.1%.

Analyst verdict

nib enters FY27 as a simpler, more focused and financially stronger group than at any point in the last five years. The completion of the travel exit in September 2026 removes a cyclical, low-margin business that contributed under 2% of Group UOP, while crystallising roughly $97m of net cash. The FY26 result demonstrated that the "adjacent" strategy is no longer aspirational: International, New Zealand, Thrive and Health Services delivered $86.1m of UOP, about a third of the total, with New Zealand's turnaround and Health Services' first full-year profit particularly important proof points for the new CEO.

The central debate is the core. Australian residents UOP has declined for two years as management deliberately guided margins into the 6–7% band and absorbed rebate, offer-cost and risk-equalisation headwinds. Policyholder growth of 1.9% fell short of the ~3% target, albeit with a better Silver-tier mix. If arhi stabilises — as guidance for broadly stable gross margins implies — nib's lower cost base and moderating own-claims inflation should allow it to compound earnings at mid-to-high single digits, consistent with FY27 guidance of $265–285m.

Against this, the stock has de-rated roughly 15% over the past year to around A$6.45, a trailing P/E of approximately 17x and a fully franked yield above 4.5% on ordinary dividends — undemanding relative to the company's ROE in the high teens and its improved balance sheet. The higher payout ratio and capital optionality provide downside support.

On balance, we view nib as a quality, reasonably valued defensive compounder whose near-term rerating depends on evidence that arhi earnings have troughed and that one-off costs genuinely fall in FY27. The principal risks are regulatory (premium approvals, rebate settings, NDIS reform) and risk-equalisation volatility. Investors should watch the 1H27 result for arhi margin stability and policyholder momentum as the key swing factor.


Derived figures are labelled. It is not investment advice; consult a licensed financial adviser before making investment decisions.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleTenureBackground

Ed Close

Managing Director & CEO

MD & CEO since 1 Dec 2024; joined nib 2017

Head of Marketing & Products, arhi (2017); CEO arhi (from 2020); led Midnight Health partnership; nib representative on Honeysuckle Health board; prior senior roles at Commonwealth Bank. Total fixed remuneration on appointment: $1,050,000 p.a. (mi-3, 29 Jul 2024)

Nick Freeman

Group Chief Financial Officer

Current (presented FY26 results)

Details in 2026 Annual Report

Rob Hennin

CEO, nib New Zealand

Current

Led NZ recovery plan

Martin Adlington

Chief Executive, nib Thrive

Current

Per InvestSMART management listing

Jordan French

Company Secretary

Current (authorised 2025–2026 releases)

Succeeded Roslyn Toms

Troy Frearson

Group Head of Performance, Planning & Investor Relations

Current

—

Board of Directors

NameRoleStatusNotes

David Gordon

Independent Non-Executive Chair

Current

Group Chair throughout CEO transition

Ed Close

Managing Director & CEO

Executive director

—

Jacqueline Chow

Independent Non-Executive Director

Current

Stepped down from nib NZ board (2023), remains on Group board

Hisham El-Ansary

Independent Non-Executive Director

Appointed 2 Dec 2025; stands for election at 2026 AGM

Ex-CEO Bupa Asia Pacific; NED RACV; adviser to Goldman Sachs APAC; former Healthscope advisory board

Donal O'Dwyer

Former NED

Retired 6 Nov 2025

Joined March 2016; Audit, People & Remuneration, Nominations committees

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypePositioning vs nib

arhi

Medibank Private (incl. ahm) — ASX: MPL

Listed, for-profit

Market leader (~27% share, APRA approx.); larger scale, also health services

arhi

Bupa ANZ

Foreign-owned (UK Bupa, mutual-like)

#1/#2 (~25% share approx.); vertically integrated (dental, aged care, optical)

arhi

HCF

Not-for-profit mutual

~12% share approx.; strong NSW base

arhi

HBF

Not-for-profit mutual

~7% share approx.; dominant in WA

arhi

Australian Unity / Teachers Health / CBHS / GMHBA / Peoplecare

Mutuals / NFP

Niche and regional; often more price-competitive

International

Allianz Care, Medibank (OSHC/OVHC), Bupa, ahm OSHC, CBHS International

Mixed

Competitive OSHC/OVHC panel market

New Zealand

Southern Cross Health Society

NZ not-for-profit

Dominant NZ health insurer (majority share)

New Zealand

AIA NZ, Partners Life, Accuro, UniMed

Various

nib a strong #2 in NZ health

NDIS plan management

Plan Partners, My Plan Manager, Leap in!, numerous small providers

Private

nib Thrive among larger, scaled providers

Health services / distribution

Compare the Market, iSelect, Medibank Health, Bupa health services

Various

ItsMyGroup facilitates >10% of industry PHI sales

Competitor Detail

Metricnib (FY26)

Group revenue (AUD Bn)

3.85

Revenue growth (%)

6.2

Operating expense ratio (%)

16.6

arhi/resident net margin (%)

6–7 target

Recent Developments

--

Company Snapshot

1952

Founded

Newcastle, Australia

Headquarters

SWOT Analysis

Strengths

  • Earnings recovery and diversification: Group UOP +9.1% to $260.9m in FY26; adjacent businesses $86.1m (+$41.9m), ~one-third of earnings (FY26 Investor Presentation).
  • Cost leadership: OER down 110bps to 16.6%; arhi non-marketing expense ratio 5.3%, lowest since 2007 (FY26 ASX Announcement).
  • Balance sheet: Debt down to $204.8m; gearing 15.2%; leverage 0.6x; PCA ratio 1.65x (FY26).
  • Growth engine: Record arhi sales; 85% of net growth in target Silver tier (FY26 webcast).
  • Digital efficiency: 86.3% claims automated, 94.8% processed within 24 hours; NPS +32 (FY26).
  • International franchise: UOP $35.1m (+15.1%), NPS +62, policyholders +4.4% (FY26).
  • Cash generation: Net operating cash $199.1m vs $165.7m (FY26).

Weaknesses

  • arhi UOP decline: Down 9.6% to $187.9m in FY26 after −4.6% in FY25.
  • NPAT sensitivity: FY26 NPAT −5.9% as investment income fell 27.8% to $57.0m.
  • Persistent one-offs: One-off, M&A and integration costs $23.7m (FY26) and $21.5m (FY25).
  • Slowing policyholder growth: arhi net growth 1.9% (FY26) vs 3.2% (FY25) and ~3% target.
  • NZ execution history: Loss of $2.9m in FY25 required aggressive repricing; NPS fell to +2 in 1H26.
  • Thrive participant decline: Participants down 6.9% to 42,070 at 31 Dec 2025; UOP −3.6% FY26.
  • Scale gap: Market share well below Medibank and Bupa (APRA statistics).

Opportunities

  • Capital deployment: ~$97m net Travel proceeds; ~$73m remaining after special dividend (FY26).
  • FY27 growth guidance: UOP $265–285m excl. Travel implies 3.5–11.3% growth on $256.1m.
  • Industry claims inflation gap: nib's 4.1% claims inflation vs accelerating industry inflation could support relative pricing.
  • NDIS reform: Plan management reforms expected to favour scaled, compliant providers (FY26).
  • Health services scaling: Health Services income +46% to $25.4m; ItsMyGroup >10% of industry PHI sales.
  • AI productivity: $61m value in FY26; further OER reduction targeted for FY27.
  • PALM and skilled migration demand supporting International growth.

Threats

  • Risk equalisation volatility: Explicitly cited as a FY26 headwind and FY27 guidance caveat.
  • Regulatory pressure on premiums and the annual approval process amid cost-of-living concerns.
  • Hospital sector funding pressure: Hospital benefits payout ratio 88.8%, above pre-COVID; contract disputes possible.
  • Government rebate/levy changes: Historical AGR and NSW HIL adjustments hit 1H26 one-offs.
  • International student caps constraining OSHC growth.
  • NZ medical inflation: Claims inflation still 12% in FY26.
  • Investment market volatility: Net investment income swings (e.g., FY22 investment losses drove NPAT −16.6%).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2025Strategic review of nib Travel announcedSignalled portfolio simplification under new CEO
25 Aug 2025FY25 results: revenue $3.6bn (+7.8%), UOP $239.2m (−7.1%), NPAT $198.6m (+9.4%), DPS 29cIn line with guidance; shares rallied to 52-week high
25 Aug 2025FY26 targets: arhi net policyholder growth ~3%, net margin 6–7%, NZ profitableSet expectations for recovery year
25 Aug 2025Andrew Blair appointed nib NZ director (Chair from 1 Nov 2025)NZ governance renewal
23 Sep 2025CEO Ed Close sells ~53.7k shares at ~$7.40Insider sale near price highs
9 Oct 20252025 Notice of AGM releasedFive-year performance table
6 Nov 20252025 AGM; Donal O'Dwyer retires as NEDBoard renewal
2 Dec 2025Hisham El-Ansary joins BoardAdds health-insurance executive depth
Dec 2025Update: ~$17m non-recurring expenses expected in 1H26 (above prior guidance); UOP on trackOne-offs elevated
28 Jan 2026Notification regarding unquoted securitiesRoutine
13 Feb 2026Sale of World Nomads to IMG/SiriusPoint for $67.5mFirst leg of travel exit
17 Feb 20262026 premium changes announced (average 5.47% effective 1 Apr 2026)Key revenue driver
23 Feb 20261H26 results: UOP $129.1m (+22.0%), NPAT $82.9m, EPS 17.0c, DPS 13c; FY26 UOP guidance $257–267mStrong first half; adjacent UOP $30.4m best since FY19
23 Feb 2026Historical adjustments for Australian Government Rebate and NSW Health Insurance Levy in one-offsRegulatory clarification cost
26 Mar 2026Dividend/distribution updateDRP pricing
8 Apr 2026Interim dividend paid; quotation of DRP sharesCapital management
16 Apr 2026Cessation/unquoted securities notificationsEmployee incentive plans
14 May 2026Chair David Gordon buys 5,000 shares at $6.563Insider buying
5 Jun 2026Sale of AU/NZ travel to Allianz Partners (up to $50m) + distribution partnershipConcludes review; shares rose strongly in following weeks
6 Jul 2026Cessation of securities notificationRoutine
17 Jul 2026Notice of FY26 results briefingRoutine
30 Jul 2026ACCC clears Allianz Partners acquisitionRemoves regulatory hurdle
24 Aug 2026FY26 results: UOP $260.9m (+9.1%), NPAT $186.9m, DPS 34c incl. 5c special, payout target 65–75%Diversification paying off
24 Aug 2026FY27 guidance UOP $265–285m excl. TravelGrowth guided; shares fell from July levels
4 Sep 2026Record date for final dividend—
17 Sep 2026Allianz Partners transaction completesTravel exit
30 Sep 2026World Nomads sale to IMG completesTravel exit complete
1 Oct 2026ASX: nib concludes sale of nib TravelFinal milestone
7 Oct 2026Final dividend (21.0c incl. 5c special) paidCapital returned
Oct/Nov 2026 (expected)2026 AGM; El-Ansary stands for electionGovernance

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Group underlying revenue rose from AUD 2,788.6 Mn in FY2022 to AUD 3,854.8 Mn in FY2026.
Nib Holdings Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Group underlying revenue2,788.63,0513,337.23,599.23,854.8
Insurance revenue———3,461.43,685.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.